MAY 05, 2017 5:18 AM PDT

How a Cancer-Causing Virus Hides in Plain Sight

WRITTEN BY: Xuan Pham

It’s estimated that nine out of ten people are infected with the Epstein-Barr virus (EBV). The virus stays dormant for most of the time, but in some cases, it rears its ugly self to cause lymphoma in immunocompromised people. How does the virus manage to conceal itself so well within our bodies only to strike when we’re most vulnerable? Scientists think it’s the virus’ ability to masquerade within our immune cells.

Image credit: wikipedia.org

Since its discovery in the 1960s, the Epstein-Barr virus has proven to be increasingly more complex. Also called human herpesvirus 4 (HHV-4), EBV is one of eight viruses in the herpes family. It’s infamous for causing “the kissing disease,” otherwise known as mono (short for mononucleosis), in teenagers.

But even more threatening than causing swollen lymph glands and fevers, EBV was the first virus shown to cause cancer directly. In particular, EBV infection is linked to two types of lymphomas (Burkitt’s and Hodgkin’s), stomach cancer, and some types of head and neck cancer (nasopharyngeal carcinoma).

EBV typically persists in a type of immune cells called B cells - these are white blood cells that respond to infection. And from within, the virus manages to boost B cell division while simultaneously stalling cell death.

"The virus actually taps into the B cell's normal protection against apoptosis," said Micah Luftig, an associate professor of molecular genetics and microbiology at Duke University, and the study's senior investigator.

By this mechanism, EBV manages to immortalize the B cells, and thereby furthering its own survival. Specifically, as the infection progresses, EBV will blend in with memory B cells, a B-cell subtype that circulate throughout the body, ready to respond to attacks by known pathogens.

"All of this is about establishing latency," Luftig said. This is how EBV hides in plain sight. The team used a technique called BH3 profiling to “query mitochondrial regulation of apoptosis,” which allowed them to glimpse the mechanism behind B-cell immortalization by the virus. Key to the story is a protein called EBNA3A (Epstein-Barr Nuclear Antigen 3A), which plays an crucial role in the B cell’s abilities to resist apoptosis.

Ultimately, Luftig hopes this line of research could lead to new treatment options and benefit immunocompromised people who are at much higher risk of developing cancer from the Epstein-Barr virus.

Additional source: Duke University via EurekAlert!

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 09, 2020
Cancer
Microbubbles enhance delivery of chemotherapy drug
SEP 09, 2020
Microbubbles enhance delivery of chemotherapy drug
New research published in APL Bioengineering reports on a new technology developed by scientists at Tulane Universi ...
OCT 07, 2020
Cancer
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
OCT 07, 2020
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
Over the years, cancer researchers have struggled not just with drug and diagnostic design, but with drug delivery. The ...
OCT 05, 2020
Cancer
Fighting mitochondrial terminal exhaustion
OCT 05, 2020
Fighting mitochondrial terminal exhaustion
New findings reported in Nature Immunology highlight how the tumor microenvironment attacks the mitochondria of T l ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 03, 2020
Genetics & Genomics
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
NOV 03, 2020
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
Genetic sequencing technologies have rapidly advanced, reducing the time required to sequence the entire human genome fr ...
NOV 13, 2020
Cancer
Predictive model assesses risk of adverse side effects for chemotherapy patients
NOV 13, 2020
Predictive model assesses risk of adverse side effects for chemotherapy patients
New research published in npj Systems Biology and Applications showcases a model capable of predicting which patien ...
Loading Comments...